RBCC Partner N3D Could Revolutionize Toxicity Testing

  RBCC Partner N3D Could Revolutionize Toxicity Testing

Business Wire

NOKOMIS, Fla. -- January 30, 2013

New research indicates that 3-D cell culturing technology developed by Rainbow
Coral Corp. (OTCBB: RBCC) partner Nano 3D BioSciences (n3D) could make
toxicity tests for airborne chemicals faster and more effective than ever
before.

In collaboration with scientists at Rice University, Dr. Glauco Souza of n3D
led a research study that demonstrates the potential of the company’s magnetic
levitation tech to grow some of the most realistic lung tissue produced in a
laboratory. In the study, researchers combined four types of human cells to
replicate three-dimensional tissues from the wall of the bronchiole, found
deep inside the lung.

Using traditional 2-D cell cultures, producing cells at the air-liquid
interface, ideal for toxicity testing, is enormously difficult. Using n3D
technology, however, researchers were able to magnetically levitate bronchiole
tissue to the air-liquid interface so that airborne toxins can be exposed to
the epithelial layer of the tissue, just as would occur in human lungs.

The same methods have also been used to culture heart valve tissue. RBCC
believes that its joint venture partner’s technology is on the cusp of
becoming standard equipment in cellular research labs around the globe.

“Scientists everywhere are discovering that n3D’s Bio-Assembler technology can
produce superior cell cultures for a broad range of research fields,” said
RBCC CEO Patrick Brown. “As more and more high-profile cell researchers
discover this system’s potential, the market for the technology will continue
to grow exponentially.”

The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly
technology allows it to produce accurate, 3D representations ofin
vivotissues faster and easier than any other existing tools. The incredible
device is key to RBCC’s plans to participate in the impressive upside in store
for n3D.

“Previously, when I worked at Baylor College of Medicine, we used transwells
to study human bronchial epithelial cells,” said n3D scientist Jacob Gage, who
co-authored the bronchiole study. “After switching to the Bio-Assembler, we
were able to culture multiple cell types to generate an in vivo-like
environment. This gave us the opportunity to create truly three-dimensional
and histologically accurate structures.”

For more information on Rainbow BioSciences, please
visitwww.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen, Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
 
Press spacebar to pause and continue. Press esc to stop.